Inflammation markers could guide depression treatments

January 12, 2016
Credit: George Hodan/Public Domain

Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.

New research from Emory University School of Medicine is providing hints as to which forms of depression may respond best to drugs that target .

The findings are scheduled for publication online on January 12 in Molecular Psychiatry.

Depressed patients with signs of have elevated levels of glutamate in regions of the brain that are important for motivation, the researchers have found.

"Our results suggest that markers can guide us to which depressed patients respond best to glutamate blockers," says lead author Ebrahim Haroon, MD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute. "This could be an important step toward personalizing treatment for depression."

Glutamate is a chemical messenger used by neurons to communicate. However, at high levels, it can become toxic to both neurons and glia, cells that support brain health. It is unlikely that the elevated levels seen in some depressed patients are acutely toxic, Haroon says.

"Still, we think that one of the ways that inflammation may harm the brain and cause depression is by increasing levels of glutamate in sensitive regions of the brain, possibly through effects on glia," he says.

Researchers examined 50 patients with depression who were not receiving antidepressant medication at that time. Inflammation was determined by a blood test for C-reactive protein (CRP), which was measured on repeat visits to make sure its levels were stable.

The team used an imaging technique called (MRS) to measure in the , a brain region important for motor control, motivation and decision making. The researchers also measured levels of myo-inositol, a marker of glial health.

High glutamate and myo-inositol levels in the basal ganglia were associated with patients' reports of anhedonia, an inability to experience pleasure, and slow motor function, as measured by finger tapping speed.

"We focused on the basal ganglia because we had previously seen that a treatment for hepatitis C virus that arouses inflammation and can trigger depressive symptoms could also increase glutamate levels there," Haroon says.

He adds that the paper's findings do not directly address how ketamine and other glutamate-targeting drugs may work against depression, but may indicate which patients would be likely candidates.

A previous study of people with difficult-to-treat found that only those with high tended to improve in response to the anti-inflammatory antibody infliximab.

Explore further: Inflammation linked to weakened reward circuits in depression

More information: E Haroon et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression, Molecular Psychiatry (2016). DOI: 10.1038/mp.2015.206

Related Stories

Inflammation linked to weakened reward circuits in depression

November 20, 2015
About one third of people with depression have high levels of inflammation markers in their blood. New research indicates that persistent inflammation affects the brain in ways that are connected with stubborn symptoms of ...

Depressed females have over-active glutamate receptor gene

July 30, 2015
Numerous genes that regulate the activity of a neurotransmitter in the brain have been found to be abundant in brain tissue of depressed females. This could be an underlying cause of the higher incidence of suicide among ...

Uncovering the source of inflammatory malaise

October 22, 2012
(Medical Xpress)—A study conducted by researchers at Emory indicates that inflammation targets a part of the brain called the basal ganglia, causing symptoms of depression and fatigue. The study was recently reported in ...

Countering brain chemical could prevent suicides

December 14, 2012
(Medical Xpress)—Researchers have found the first proof that a chemical in the brain called glutamate is linked to suicidal behavior, offering new hope for efforts to prevent people from taking their own lives.

Study offers insight on how a new class of antidepressants works

September 30, 2015
A new class of drugs under development to treat depression has shown some success by targeting brain cells' ability to respond to the chemical messenger glutamate. But the mechanism by which these experimental therapies work ...

Would an 'anti-ketamine' also treat depression?

November 18, 2013
Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. ...

Recommended for you

Gene associated with schizophrenia risk regulates neurodevelopment

September 25, 2017
A gene associated with the risk of schizophrenia regulates critical components of early brain development, according to a new study led by researchers from Penn State University. The gene is involved in the translation of ...

Child abuse affects brain wiring

September 25, 2017
Researchers from the McGill Group for Suicide Studies, based at the Douglas Mental Health University Institute and McGill University's Department of Psychiatry, have just published research in the American Journal of Psychiatry ...

For a better 'I,' there needs to be a supportive 'we'

September 25, 2017
If you're one of those lucky individuals with high motivation and who actively pursues personal growth goals, thank your family and friends who support you.

Babies can learn that hard work pays off

September 21, 2017
If at first you don't succeed, try, try again. A new study from MIT reveals that babies as young as 15 months can learn to follow this advice. The researchers found that babies who watched an adult struggle at two different ...

Study links brain inflammation to suicidal thinking in depression

September 21, 2017
Patients with major depressive disorder (MDD) have increased brain levels of a marker of microglial activation, a sign of inflammation, according to a new study in Biological Psychiatry by researchers at the University of ...

Oxytocin turns up the volume of your social environment

September 20, 2017
Before you shop for the "cuddle" hormone oxytocin to relieve stress and enhance your social life, read this: a new study from the University of California, Davis, suggests that sometimes, blocking the action of oxytocin in ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

oliverlu70
not rated yet Jan 12, 2016
More physicalist smoke and mirrors, my question is, when the pendulum swings back towards psychological explanations for mental illness what will the new paradigm(s) look like? (The only thing we know for sure is that they *won't* be Freudian because that's already been done and tried.)

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.